Skip to main content

Table 1 Tumors with high proportions of A:T > T:A mutations

From: Mutation signatures implicate aristolochic acid in bladder cancer development

  

Mutations attributed to AA

Mutation count

A:T > T:A proportion

A > T Count

Non-transcribed

/(all A > T)

Strand bias

A:T > T:A cosine similarity with AA signature

Sample

Cancer type

Proportion

Total

A:T > T:A

P

FDR

Non-transcribed

Transcribed

 

P

FDR

9T

UTUC

0.97

2386

2008

0

0

1505

503

0.75

8E-116

3E-113

0.987

20T

UTUC

0.96

1933

1641

0

0

1265

376

0.77

1E-112

2E-110

0.995

K100T

UTUC

0.97

2342

1982

0

0

1435

547

0.72

9E-92

1E-89

0.992

6T

UTUC

0.95

1552

1302

0

0

994

308

0.76

1E-84

9E-83

0.995

K80T

UTUC

0.98

1713

1480

0

0

1100

380

0.74

1E-81

1E-79

0.988

13T

UTUC

0.99

1409

1222

0

0

924

298

0.76

3E-75

2E-73

0.994

K79T

UTUC

0.99

1573

1374

0

0

1015

359

0.74

5E-73

3E-71

0.992

130T

Bladder

0.82

1366

980

0

0

708

272

0.72

1E-45

5E-44

0.992

HK41T

HCC

0.95

781

630

0

0

441

189

0.70

2E-24

7E-23

0.988

3T

UTUC

0.91

666

524

0

0

369

155

0.70

2E-21

6E-20

0.959

136T

Bladder

0.73

688

450

1E-229

4E-228

339

111

0.75

3E-28

1E-26

0.987

10T

UTUC

0.73

545

351

3E-176

9E-175

263

88

0.75

1E-21

4E-20

0.972

HK2B_8d2

AA-treated cell line

0.73

413

264

7E-132

2E-130

178

86

0.67

8E-09

2E-07

0.972

GZ75T

HCC

0.71

404

250

4E-120

1E-118

167

83

0.67

6E-08

2E-06

0.975

HK2_AA

AA-treated cell line

0.66

261

152

2E-68

4E-67

107

45

0.70

3E-07

6E-06

0.905

33324197T

Bladder

0.42

182

67

5E-17

1E-15

46

21

0.69

2E-03

3E-02

0.942

B23

Bladder

0.36

241

76

9E-15

2E-13

56

20

0.74

2E-05

4E-04

0.949

HK174T

HCC

0.48

109

46

1E-14

2E-13

24

22

0.52

0.44

0.85

0.886

HK65T

HCC

0.47

119

48

2E-14

5E-13

41

7

0.85

3E-07

7E-06

0.889

B77

Bladder

0.45

106

42

2E-12

4E-11

38

4

0.90

3E-08

8E-07

0.927

HK81T

HCC

0.45

101

39

3E-11

5E-10

26

13

0.67

3E-02

0.26

0.893

GZ119T

HCC

0.46

59

25

1E-08

2E-07

17

8

0.68

5E-02

0.40

0.736

B89-12

Bladder

0.3

238

62

1E-08

2E-07

48

14

0.77

9E-06

2E-04

0.950

HK267T

HCC

0.43

61

23

5E-07

8E-06

18

5

0.78

5E-03

7E-02

0.833

HK75T

HCC

0.41

67

24

9E-07

1E-05

12

12

0.50

0.58

1

0.871

21T

UTUC

0.34

76

24

1E-05

2E-04

17

7

0.71

3E-02

0.27

0.860

TCGA-K4-A6FZ-01A-11D-A31L-08

Bladder

0.18

461

83

4E-04

6E-03

52

31

0.63

1E-02

0.15

0.525

1T

UTUC

0.27

70

18

2E-03

3E-02

17

1

0.94

7E-05

1E-03

0.777

  1. HCC, hepatocellular carcinoma; NA, not applicable; UTUC, upper urinary tract urothelial cell carcinoma.